Arbutus sues Pfizer and BioNTech over LNP patents in 3 countries
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/21/2026
- Wall St futures gain as chip stocks extend recovery; earnings in focus
- Oil prices rise nearly 2% on fresh attacks by US and Iran
- Chip stocks extend global rebound following last week's rout
- Adobe, Salesforce and Intuit fall as Morgan Stanley begins cautious coverage
- Danaher shares tumble despite earnings beat
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- NVIDIA reports 9.3% passive stake in Nebius
- Intersnack to acquire Utz Brands at $14.25 per share in go-private deal
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to
July 16, 2026 7:30 AM EDTArbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their innovative lipid nanoparticle (LNP) technology against Pfizer and BioNTechÂ
Received approximately $178M from Moderna as Arbutus share of the noncontingent payment under the March 2026 Settlement Agreement resolving litigation over Modernas infringement of Arbutus LNP patents
Anticipates receipt of a dividend from Genevant in Q3 2026
Expects to return up to approximately $230M in capital to Arbutus shareholders
WARMINSTER, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma... More
